Serzone was approved by the FDA for use in the United States for the treatment of depression in 1994. An anti-depressant in a class of its own in terms of its structure and composition, Serzone shares some characteristics with other serotonin uptake inhibitors like Prozac, Paxil and Zoloft. It is used to relieve feelings of sadness, worthlessness, or guilt; other symptoms of depression such as loss of interest in daily activities; changes in appetite; tiredness; sleeping too much; insomnia; and thoughts of death or suicide. The drug Serzone generates annual sales of $400 million for its manufacturer, Bristol-Myers Squibb. On May 19th, 2004, Bristol-Myers Squibb announced that due to declining sales, Serzone will no longer be sold in the U.S. after June 14th, 2004. This action does not affect sales of generic versions of Serzone (nefazodone).
- About US
- Our Practice Areas